{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:17:20Z","timestamp":1790835440035,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pyoderma, commonly known as impetigo, is a bacterial skin infection causing pus formation, prevalent globally, especially in resource-poor areas. It affects both children and adults, including those with conditions like diabetes. Despite its significant impact and economic burden, research on its global epidemiology is limited. This study aims to address this gap by analyzing pyoderma trends from 1990 to 2019 using GBD data. The study aims to analyze global trends in pyoderma epidemiology from 1990 to 2019 using GBD data. Specifically, it investigates Age-Standardized Incidence Rate (ASIR), Mortality Rate (ASMR), and Disability-Adjusted Life Years Rate (ASDR) across 204 countries. Additionally, it provides insights into demographic and socioeconomic factors influencing pyoderma prevalence. Furthermore, it forecasts pyoderma\u2019s development trends for the next decade to inform public health strategies. Data were sourced from the GBD 2019 database, comprising various sources such as censuses, surveys, and registries. Estimates for pyoderma incidence, mortality, and DALYs, along with their 95% uncertainty intervals (UI), were retrieved. The Sociodemographic Index (SDI) was used to assess socioeconomic status, and statistical calculations were performed using the WHO Health Equity Assessment Toolkit and R software (v4.3.2). From 1990 to 2019, the Age-Standardized Incidence Rate (ASIR) and Age-Standardized Mortality Rate (ASMR) of impetigo increased, while the Age-Standardized Disability-Adjusted Life Years Rate (ASDR) declined. Significant global geographical heterogeneity persists, closely associated with the Sociodemographic Index (SDI). Children under 5 and the elderly are particularly at risk, with lower SDI nations bearing higher burdens. Population growth and aging contribute to this rise, with disparities in impetigo trends persisting among countries and regions with varying SDI levels, expected to continue until 2030. Pyoderma exhibits significant heterogeneity across age, gender, and geography, with pronounced disparities evident in underdeveloped regions or countries. Therefore, prioritizing policy formulation and implementing tailored prevention and treatment strategies for high-risk populations are imperative to alleviate the disease burden effectively. Such targeted approaches are crucial in addressing the global impact of pyoderma.<\/jats:p>","DOI":"10.1038\/s41598-025-85995-z","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T10:38:40Z","timestamp":1736764720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The global, regional, and national patterns of change in the burden of bacterial pyoderma from 1990 to 2019 and the forecast for the next decade"],"prefix":"10.1038","volume":"15","author":[{"given":"Hao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"8","key":"85995_CR1","doi-asserted-by":"publisher","first-page":"e0136789","DOI":"10.1371\/journal.pone.0136789","volume":"10","author":"AC Bowen","year":"2015","unstructured":"Bowen, A. C. et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS ONE 10 (8), e0136789 (2015).","journal-title":"PLoS ONE"},{"issue":"9960","key":"85995_CR2","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/S0140-6736(14)61395-7","volume":"384","author":"JC van der Wouden","year":"2014","unstructured":"van der Wouden, J. C. & Koning, S. Treatment of impetigo in resource-limited settings. Lancet 384 (9960), 2090\u20132091 (2014).","journal-title":"Lancet"},{"issue":"6","key":"85995_CR3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","volume":"134","author":"RJ Hay","year":"2014","unstructured":"Hay, R. J. et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J. Investig. Dermatol. 134 (6), 1527\u20131534 (2014).","journal-title":"J. Investig. Dermatol."},{"issue":"5","key":"85995_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1473-3099(18)30790-4","volume":"19","author":"L Romani","year":"2019","unstructured":"Romani, L. et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect. Dis. 19 (5), 510\u2013518 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"85995_CR5","doi-asserted-by":"crossref","unstructured":"Koning, S. et al. Interventions for impetigo. Cochrane Database Syst. Rev. 2, CD003261 (2004).","DOI":"10.1002\/14651858.CD003261.pub2"},{"key":"85995_CR6","unstructured":"World Health Organization. Epidemiology and Management of Common Skin Diseases in Children in Developing Countries, vol. WHO\/FCH\/CAH\/05.12 (World Health Organization, 2005)."},{"issue":"6","key":"85995_CR7","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.pcl.2009.09.002","volume":"56","author":"RM Andrews","year":"2009","unstructured":"Andrews, R. M., McCarthy, J., Carapetis, J. R. & Currie, B. J. Skin disorders, including pyoderma, scabies, and tinea infections. Pediatr. Clin. N. Am. 56 (6), 1421\u20131440 (2009).","journal-title":"Pediatr. Clin. N. Am."},{"issue":"7457","key":"85995_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/bmj.329.7457.95","volume":"329","author":"MJ Sladden","year":"2004","unstructured":"Sladden, M. J. & Johnston, G. A. Common skin infections in children. BMJ 329 (7457), 95\u201399 (2004).","journal-title":"BMJ"},{"issue":"4","key":"85995_CR9","first-page":"229","volume":"90","author":"H Hartman-Adams","year":"2014","unstructured":"Hartman-Adams, H., Banvard, C. & Juckett, G. Impetigo: diagnosis and treatment. Am. Fam. Phys. 90 (4), 229\u2013235 (2014).","journal-title":"Am. Fam. Phys."},{"issue":"8","key":"85995_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S1473-3099(15)00132-2","volume":"15","author":"L Romani","year":"2015","unstructured":"Romani, L., Steer, A. C., Whitfeld, M. J. & Kaldor, J. M. Prevalence of scabies and impetigo worldwide: a systematic review. Lancet Infect. Dis. 15 (8), 960\u2013967 (2015).","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"85995_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.5694\/j.1326-5377.2001.tb143394.x","volume":"174","author":"AV White","year":"2001","unstructured":"White, A. V., Hoy, W. E. & McCredie, D. A. Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life. Med. J. Aust. 174 (10), 492\u2013496 (2001).","journal-title":"Med. J. Aust."},{"issue":"4","key":"85995_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(04)00975-2","volume":"4","author":"M McDonald","year":"2004","unstructured":"McDonald, M., Currie, B. J. & Carapetis, J. R. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect. Dis. 4 (4), 240\u2013245 (2004).","journal-title":"Lancet Infect. Dis."},{"issue":"6958","key":"85995_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/bmj.309.6958.848","volume":"309","author":"RJ Hay","year":"1994","unstructured":"Hay, R. J. et al. Wastage of family income on skin disease in Mexico. BMJ 309 (6958), 848 (1994).","journal-title":"BMJ"},{"issue":"10258","key":"85995_CR14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD Diseases","year":"2020","unstructured":"Diseases, G. B. D. & Injuries, C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of Disease Study 2019. Lancet 396 (10258), 1204\u20131222 (2020).","journal-title":"Lancet"},{"issue":"10258","key":"85995_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0140-6736(20)31404-5","volume":"396","author":"GBDV Collaborators","year":"2020","unstructured":"Collaborators, G. B. D. V. Five insights from the global burden of Disease Study 2019. Lancet 396 (10258), 1135\u20131159 (2020).","journal-title":"Lancet"},{"issue":"10311","key":"85995_CR16","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/S0140-6736(21)01546-4","volume":"398","author":"GBDAM Collaborators","year":"2021","unstructured":"Collaborators, G. B. D. A. M. Global, regional, and national mortality among young people aged 10\u201324 years, 1950\u20132019: a systematic analysis for the global burden of Disease Study 2019. Lancet 398 (10311), 1593\u20131618 (2021).","journal-title":"Lancet"},{"key":"85995_CR17","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.jinf.2016.04.024","volume":"72","author":"DK Yeoh","year":"2016","unstructured":"Yeoh, D. K., Bowen, A. C. & Carapetis, J. R. Impetigo and scabies\u2014Disease burden and modern treatment strategies. J. Infect. 72, S61\u2013S67 (2016).","journal-title":"J. Infect."},{"key":"85995_CR18","doi-asserted-by":"publisher","first-page":"1145513","DOI":"10.3389\/fpubh.2023.1145513","volume":"11","author":"A Yakupu","year":"2023","unstructured":"Yakupu, A. et al. The burden of skin and subcutaneous diseases: findings from the global burden of disease study 2019. Front. Public Health. 11, 1145513 (2023).","journal-title":"Front. Public Health"},{"issue":"6","key":"85995_CR19","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1371\/journal.pntd.0000467","volume":"3","author":"AC Steer","year":"2009","unstructured":"Steer, A. C. et al. High burden of impetigo and scabies in a tropical country. PLoS Negl. Trop. Dis. 3 (6), e467 (2009).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"85995_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1365-2133.2007.07969.x","volume":"157","author":"S Rortveit","year":"2007","unstructured":"Rortveit, S. & Rortveit, G. Impetigo in epidemic and nonepidemic phases: an incidence study over 4(1\/2) years in a general population. Br. J. Dermatol. 157 (1), 100\u2013105 (2007).","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"85995_CR21","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/jac\/dkr102","volume":"66","author":"S Rortveit","year":"2011","unstructured":"Rortveit, S., Skutlaberg, D. H., Langeland, N. & Rortveit, G. Impetigo in a population over 8.5 years: incidence, fusidic acid resistance and molecular characteristics. J. Antimicrob. Chemother. 66 (6), 1360\u20131364 (2011).","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"85995_CR22","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10096-011-1179-0","volume":"30","author":"M Dalager-Pedersen","year":"2011","unstructured":"Dalager-Pedersen, M., Sogaard, M. & Schonheyder, H. C. Staphylococcus aureus skin and soft tissue infections in primary healthcare in Denmark: a 12-year population-based study. Eur. J. Clin. Microbiol. Infect. Dis. 30 (8), 951\u2013956 (2011).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"5","key":"85995_CR23","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/JCM.01984-06","volume":"45","author":"AJ O\u2019Neill","year":"2007","unstructured":"O\u2019Neill, A. J., Larsen, A. R., Skov, R., Henriksen, A. S. & Chopra, I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J. Clin. Microbiol. 45 (5), 1505\u20131510 (2007).","journal-title":"J. Clin. Microbiol."},{"issue":"9","key":"85995_CR24","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1128\/AAC.48.9.3594-3597.2004","volume":"48","author":"AJ O\u2019Neill","year":"2004","unstructured":"O\u2019Neill, A. J., Larsen, A. R., Henriksen, A. S. & Chopra, I. A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob. Agents Chemother. 48 (9), 3594\u20133597 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"85995_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/jac\/dkm532","volume":"61","author":"AR Larsen","year":"2008","unstructured":"Larsen, A. R., Skov, R. L., Jarlier, V. & Henriksen, A. S. Epidemiological differences between the UK and Ireland versus France in Staphylococcus aureus isolates resistant to fusidic acid from community-acquired skin and soft tissue infections. J. Antimicrob. Chemother. 61 (3), 589\u2013594 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"85995_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2807\/1560-7917.ES.2022.27.49.2200245","volume":"27","author":"KEW Vendrik","year":"2022","unstructured":"Vendrik, K. E. W. et al. An unusual outbreak in the Netherlands: community-onset impetigo caused by a meticillin-resistant Staphylococcus aureus with additional resistance to fusidic acid, June 2018 to January 2020. Euro. Surveill. 27, 49 (2022).","journal-title":"Euro. Surveill."},{"issue":"8","key":"85995_CR27","doi-asserted-by":"publisher","first-page":"e2167","DOI":"10.1371\/journal.pntd.0002167","volume":"7","author":"D Engelman","year":"2013","unstructured":"Engelman, D. et al. Toward the global control of human scabies: introducing the international alliance for the control of scabies. PLoS Negl. Trop. Dis. 7 (8), e2167 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"85995_CR28","doi-asserted-by":"publisher","first-page":"155958","DOI":"10.1016\/j.metabol.2024.155958","volume":"158","author":"P Danpanichkul","year":"2024","unstructured":"Danpanichkul, P. et al. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism 158, 155958 (2024).","journal-title":"Metabolism"},{"issue":"7","key":"85995_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jamadermatol.2018.1103","volume":"154","author":"T Rosen","year":"2018","unstructured":"Rosen, T. et al. Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo: a randomized clinical trial. JAMA Dermatol. 154 (7), 806\u2013813 (2018).","journal-title":"JAMA Dermatol."},{"key":"85995_CR30","unstructured":"World Health Organization. Epidemiology and Management of Common Skin Diseases in Children in Developing Countries 54 (World Health Organization, 2005)."},{"issue":"3","key":"85995_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2471\/BLT.08.052712","volume":"87","author":"AC Steer","year":"2009","unstructured":"Steer, A. C. et al. Validation of an integrated management of childhood illness algorithm for managing common skin conditions in Fiji. Bull. World Health Organ. 87 (3), 173\u2013179 (2009).","journal-title":"Bull. World Health Organ."},{"issue":"3","key":"85995_CR32","doi-asserted-by":"publisher","first-page":"845","DOI":"10.4269\/ajtmh.16-0753","volume":"97","author":"L Romani","year":"2017","unstructured":"Romani, L. et al. The epidemiology of scabies and impetigo in relation to demographic and residential characteristics: baseline findings from the skin health intervention Fiji trial. Am. J. Trop. Med. Hyg. 97 (3), 845\u2013850 (2017).","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"85995_CR33","first-page":"135","volume":"19","author":"M Garcia-Gil Mdel","year":"2011","unstructured":"Garcia-Gil Mdel, M. et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inf. Prim. Care 19 (3), 135\u2013145 (2011).","journal-title":"Inf. Prim. Care"},{"issue":"3","key":"85995_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/pubmed\/fdg060","volume":"25","author":"C Cricelli","year":"2003","unstructured":"Cricelli, C. et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J. Public Health Med. 25 (3), 254\u2013257 (2003).","journal-title":"J. Public Health Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85995-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T10:38:46Z","timestamp":1736764726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85995-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85995"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85995-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"28 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1810"}}